MedPath

Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma

Phase 2
Completed
Conditions
Sarcoma
Registration Number
NCT00055939
Lead Sponsor
Daiichi Sankyo
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating children who have relapsed or refractory rhabdomyosarcoma.

Detailed Description

OBJECTIVES:

* Determine the objective response rate (complete and partial responses) in pediatric patients with relapsed or refractory rhabdomyosarcoma treated with exatecan mesylate.

* Determine the time to tumor progression in patients treated with this drug.

* Determine the median survival and survival at 6 and 12 months in patients treated with this drug.

* Assess pain in patients treated with this drug.

* Evaluate the quantitative and qualitative toxic effects of this drug in these patients.

* Evaluate the pharmacokinetics of this drug in these patients.

OUTLINE: This is an open-label, nonrandomized, multicenter study.

Patients receive exatecan mesylate IV over 30 minutes on days 1-5. Treatment repeats every 3 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 6 additional courses beyond CR.

PROJECTED ACCRUAL: A total of 13-27 patients will be accrued for this study within 1 year.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (9)

University of Colorado Cancer Center at University of Colorado Health Sciences Center

🇺🇸

Denver, Colorado, United States

Nemours Children's Clinic

🇺🇸

Jacksonville, Florida, United States

Cancer Institute of New Jersey

🇺🇸

New Brunswick, New Jersey, United States

Memorial Sloan-Kettering Cancer Center

🇺🇸

New York, New York, United States

St. Jude Children's Research Hospital

🇺🇸

Memphis, Tennessee, United States

Medical City Dallas Hospital

🇺🇸

Dallas, Texas, United States

Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas

🇺🇸

Dallas, Texas, United States

University of Texas - MD Anderson Cancer Center

🇺🇸

Houston, Texas, United States

Hospital for Sick Children

🇨🇦

Toronto, Ontario, Canada

University of Colorado Cancer Center at University of Colorado Health Sciences Center
🇺🇸Denver, Colorado, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.